A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement of disease-free survival in participants with resected squamous cell carcinoma of the head and neck, who are at high risk for relapse and are ineligible for high-dose cisplatin
Details
Age
Adult
Type of Study
Treatment
Locations
Greeley Campus
Harmony Campus
Medical Center of the Rockies
Poudre Valley Hospital
Principal Investigator
Steven Schuster, MD
Study ID
Protocol Number: 23-0137
More information available at ClinicalTrials.gov: NCT05386550
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers